Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom

Cancer Research UK (CRUK)

Status: Unknown

Conditions: Transitional Cell Cancer of the Renal Pelvis and Ureter; Brain and Central Nervous System Tumors; Bladder Cancer; Esophageal Cancer; Melanoma (Skin); Intraocular Melanoma; Kidney Cancer; Lymphoma; Pancreatic Cancer

Treatments: Genetic: DNA analysis; Other: laboratory biomarker analysis; Genetic: polymorphism analysis; Other: questionnaire administration

Study type: Observational

Funder types: Other

Identifiers

NCT00757614

MREC-SEARCH-CANCER

CDR0000598879

MREC-07/MRE05/17

Details and patient eligibility

About

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with cancer in East Anglia, Trent, or West Midlands of the United Kingdom.

Full description

OBJECTIVES:

• To obtain epidemiological information and biological material on a population-based series of cancer cases, including malignant melanoma, lymphoma, bladder, kidney, esophageal, and pancreatic cancer, and brain tumors.
• Identify novel cancer susceptibility genes, by comparison of genotype frequencies in cases with the corresponding frequencies in large control series.
• To estimate the age and sex-specific risks associated with variants in predisposition genes.
• To evaluate interactions between polymorphisms in predisposition genes and potential lifestyle risk factors.

OUTLINE: This is a multicenter study.

Patients complete a detailed epidemiological questionnaire that includes information on education, occupation, smoking habits, alcohol consumption, height, weight, reproductive history (age at menarche, age at pregnancies, parity, and age at menopause), oral contraceptive use, hormone replacement therapy use, family history of cancer, and past medical history.

Blood samples are collected from patients. DNA is extracted from these blood samples, from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL, and from additional controls through the European Prospective Investigation of Cancer (EPIC) study (a population-based study of diet and health based in Norfolk, East Anglia). DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes.

In addition to the cancer patients recruited for this study, patients with breast, ovarian, endometrial, colorectal, and prostate cancer are recruited for the following related clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-OVARIAN, MREC-SEARCH-ENDOMETRIAL, MREC-SEARCH-COLORECTAL, and MREC-SEARCH-PROSTATE.

Enrollment: 14,000 estimated patients

Sex: All

Ages: 18 to 69 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosed with bladder cancer, kidney cancer, esophageal cancer, pancreatic cancer, brain cancer, malignant melanoma, or lymphoma within the past 5 years

• Identified through the Cancer Research Network OR through the cancer registry serving any of the following geographic regions of the United Kingdom:

  • East Anglia
  • West Midlands
  • Trent

PATIENT CHARACTERISTICS:

• Identified by the patient's general practitioner as fit to contact for this study
• No serious mental illness or retardation

PRIOR CONCURRENT THERAPY:

• Not specified